Looks like the Venture Capital representative is out. I wonder if this means Quaker has long and shorted enough to be content and cash-out? or not. Interesting. Appears that the VC's replacement has more unique qualities, for sure.
We all know what the AF's and their (hit?) pieces/stories in stock market world are here for. How much validity the negativity in this particular story has, not withstanding, I actually do appreciate different angles and opinions about my investments.
So, let's see what CEO Mr. Lewis does now that the company is in the *cross hairs*, so-to-speak. He's had a relatively *smooth/easy* run since he took over from Whitten... mostly hiring, raising money and hitting the Conference circuit hard. Good CEO's need to handle negative circumstances well too!!!
Also, let's not forget that Lewis was part of the Hedge Fund world himself, not too long ago, either.
I understand what you're alluding to but it should be noted that he hasn't been with AEGR for over a couple of years now, I believe
Mr. Lewis did say in the last Conference that they would put out a PR when they finally reach the 100 patient enrollment for the NTM trial. Doesn't seem like it is THAT big of a deal but it's pretty clear that it has taken much longer than originally anticipated. On the plus side, though, sounding like they will not need a PH III before applying for an NDA which is terrific for patients and shareholders.
So, might we expect Management to report the findings from this study sooner than '14?
One can only imagine the Salary, Stock Options and related Strike Price Mr. Lewis' good friend is going to receive.
It's all in who you know, as they say...
Pretty cookie-cutter situation when *analyst* start working over a stock. They get to play the obvious movement (up or down) created in the share price AND possibly get a piece of the possible dilution / financing instruments. Even better, they have the closest thing to a *crystal ball*. It's indeed offensive but par for the course with the Stock Market. Like it or leave it.
Our drug works which makes the financing charade tolerable, IMO.
I could see the PH III results being a *sell the news event* because of the falsely hyped 3 day pre-announced CC not achieving Superiority but I agree, today is indeed a very strange but happy surprise!
Completely unorthodox Share Price action from most shelf offerings you normally see.
"Their indecent haste to issue shares at a 50% discount to the average valuation of the analysts has set us up for a third dilution before Arikace is finally generating revenue."
We Common Shareholders are always sheep being led to slaughter, one way or another.
Furthermore, the *analyst* are/were only here because of the usual masquerade of hoping to get a piece of the Banking/Shelf business, which still has more left, if need be, down the road.
Having said that, PHIII results were decent and NTM *should* be even better.
I guess, the participating Insti's have all ready shorted and covered because today's action up is a very, pleasant surprise, all things considered.
Well, *Cramer* pumps Novartis any chance he gets and coincidently (?), The Street had a negative article out within a nanosecond of the data release slides yesterday. I'm sure they were grateful for our 3 day heads-up PR on Friday as well...
Always a bullish sign and lots of individual investors actually seek out companies that show strong Insider Buying so this does help and is a nice gesture, for sure.
He's sitting on well over a million share options with a pretty low strike price too, though. I think he'll be OK.
Obviously, very wealthy from his Pre-Insmed successes but it is perplexing why he seemingly is the only Insider that purchases shares.
Still shaking my head on this one. It was a terrific round table discussion on the data and CC but why the hype-building PR on Friday? I don't buy REG FD obligations either. I mean, how long were they sitting on the QIDP for NTM news?!
Building hype for 3 days was gonna be a let down unless there was indeed *Superiority* type news. Very dumb move or planned? Thanks goodness there appears to be decent COH or I would be half expecting a PIPE deal or some sort of financing coming at us right down pike after this set up.
The data does give us a legitimate company asset now which is great. But a little bit of the luster has come off Mr. Lewis, though, in my eyes. He knows the market and must have known how the results would be interpreted.
BUT, it was indeed a very thorough CC and I'm assuming we'll be hearing from the analyst that cover us.
I wouldn't be surprised with reiterations and possibly upgrades.
The drug works, is once a day and is approvable. Great news for all, especially patients! NTM scenario at the very least looks to be the same if not a lot better. Especially with no currently dedicated treatments.
My only confusion is why on earth did Mr. Lewis build major hype and a set-up by a 3 day pre-announcement of the CC?!
Hoping his allegiance is 100% with us and not The Street dot coms of the world!
Mr. Lewis MUST know he is building major hype throughout the weekend with today's PR. I see the *twitterverse* is already talking about it too as I type. Most companies PR that morning followed by a CC later that day. Not saying + positive results are a slam dunk but it would be extremely unorthodox if not foolish to build hype for a bust. Matter of fact, by building such hype, it could make the stock crash harder if results are less than stellar, IMO.
Nothing really surprises with regards to Wall St. BUT, imo, it would be a real #$%$ move to pre- announce, through a weekend, a CC for negative results for a Company with our dubious history. I'm sure someone could find a precedent for this and I understand that results still could be less than stellar but I'm hoping this is Lewis ramping it up for blast off.